AstraZeneca Looking At Potential Options for COVID-19 Vaccine Business: Reuters

AstraZeneca plc (NASDAQ:AZN) is reportedly exploring its options for the future of its COVID-19 vaccine business.
The Company expects clarity on the matter by the end of 2021.
"We are exploring different options," Ruud Dobber, executive vice president and president of BioPharmaceuticals Business Unit, told Reuters about the vaccines business.
The Company generated around $894 million from COVID-19 vax sales in Q2.
Price Action: AZN shares are up 1.6% at $57.70 during the premarket session on the last check Thursday.
Image by Wilfried Pohnke from Pixabay